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METASTATIC PATTERN IN 
ADENOCARCINOMA OF 
THE LUNG 
An autopsy study from a 
cohort of 137 consecutive 
patients with complete 
resection 
A cohort of 137 patients with completely resected stage I or II adenocarci- 
noma of the lung was observed from the time of operation; the metastatic 
pattern determined at autopsy is described in relation to clinical, histologic, 
and laboratory variables. The pretreatment variables evaluated were 
performance status, age, gender, lactate dehydrogenase, stage, degree of 
differentiation, and histologic subtype of adenocarcinoma of the lung. 
Patients who survived longer than 30 days after operation were eligible for 
analysis, and 35 autopsies were performed in this patient group (autopsy 
rate: 39.8%). The most common i trathoracic metastatic sites were medi- 
astinal lymph nodes (43%), lung (31%), pleura (20%), pericardium (9%), 
and heart (6%). The most common extrathoracic sites were liver (37%), 
brain (33%), bones (21%), adrenals (17%), and kidneys (17%). Patients 
undergoing resection for stage I disease had significantly fewer intratho- 
racic metastases than patients with stage II disease (p = 0.01). Patients 
who survived less than 1 year had significantly more extrathoracic metas- 
tases than patients who survived for a longer period (p = 0.01). Patients 
with highly differentiated tumors had fewer extrathoracic metastases than 
patients with less differentiated tumors. No other statistically significant 
differences were observed. Overall, patients with stage I adenocarcinoma of 
the lung had better local control of the disease at autopsy than those with 
stage II disease, but distant metastases are a large problem despite the 
favorable prognosis of this patient group. The extrathoracic metastatic 
potential was greatest for less differentiated tumors. An active adjuvant 
systemic therapy after resection is needed in selected patients with poorly 
differentiated adenocarcinomas of the lung, even in those with stage I 
disease. (J THORAC CARDIOVASC SURG 1995;110:1130-5) 
Lars E. Stenbygaard, MD, Jens B. S0rensen, MD, and Jens E. Olsen, MD, 
Copenhagen, Denmark 
S urgery is the treatment of choice in patients with stage I or stage II non-small-cell lung cancer 
(NSCLC) and it should be performed if the patient 
is physically fit for the operation. Even with com- 
plete resection, the risk of recurrence of the disease 
is high. Adenocarcinoma of the lung (ACL) attracts 
increasing attention because the incidence of ACL is 
increasing faster than that of other major histologic 
types of lung cancer, t Some reports suggest that 
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ACL is now the most frequent histologic type. 2 The 
prognosis and treatment results of ACL may differ 
from those of the other major types of NSCLC, 3' 4 
although this is not a uniform observation. 5 The 
five-year survival after apparently complete resec- 
tion has been reported to be 40% to 69% for 
patients with stage I ACL and 25% for patients with 
stage II, 6 which emphasizes the need for adjuvant 
treatment. A detailed knowledge of the metastatic 
pattern in this disease is necessary to design appro- 
priate programs for detection of relapse. It is also 
important o know whether any clinical variables 
predict specific metastatic patterns and may there- 
fore be used in the selection of patient groups for 
adjuvant reatment. 
Several studies, most of which were published 
three to four decades ago, have focused on autopsy 
findings in NSCLC. 7-a2 Most of these studies in- 
cluded very heterogeneous patient populations, with 
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Table I. Pretreatment characteristics for patients urviving less than and more than 30 days after operation 
Patients urviving >>-30 days 
Patients urviving <30 days postoperatively and autopsy All patients undergoing 
postoperatively (n = 8) performed (n = 35) resection (n = 137) 
Male/female 7/1 19/16 68/69 
Age in years: median (range) 65 (58-74) 61 (42-75) 60 (37-79) 
LDH (U/L): median (range) 399 (280-420) 356 (138-1110) 341 (138-1110) 
Survival in days: median (range) 17 (0-29) 702 (36-2238) 960 (0-2560+) 
Histologic subtypes 
Acinar 3 15 78 
Papillary 2 7 16 
Bronchioloalveolar 3 6 24 
Solid carcinoma with mucus formation 0 7 19 
Degree of differentiation 
High 0 8 29 
Moderate 2 9 36 
Poor 6 18 72 
Performance status (WHO) 
0 2 18 77 
1 5 14 53 
2 1 3 7 
Stage (AJC) 
I 4 22 111 
II 4 13 26 
AJC, American Joint Committee on Cancer; WHO, World Health Organization. 
all stages and different reatment modalities, making 
firm conclusions difficult. Autopsy of patients with 
cancer has previously been a routine procedure in 
many countries. More recently, the autopsy rate has 
declined substantially because of changes in the 
legal basis and also in the attitude of the popula- 
tion, 13-15 so that autopsy studies are increasingly 
difficult to obtain. 
The purpose of  the current study was to evalu- 
ate the metastat ic pattern in relation to a variety 
of  clinical, histologic, and laboratory parameters  
at the time of operat ion in a well -described cohort  
of  patients with completely resected stage I or 
stage I I  ACE  Prognosis and determinants of  
survival in this pat ient group have been described 
previous ly)  6 
Patients and methods 
A cohort of patients in eastern Denmark who under- 
went complete resection of ACL stage I or stage II 
lesions during the period February 1981 through July 
1985 were analyzed for prognostic variables. Preopera- 
tively staging with mediastinoscopy or computed to- 
mography of the mediastinum, or both, was done in all 
patients. Biopsy-proven disease spread to the mediasti- 
num (stage III) was regarded as a sign of inoperability, 
and these patients were not included in the clinical trial. 
Lymphadenectomy or lymph node sampling was not 
routinely performed) 6 If a patient had symptoms re- 
lated to metastatic disease, further examinations were 
performed before the patient was included in the 
operative trial and analyses. 16 All patients were subse- 
quently followed up for survival and for metastatic 
pattern in case of autopsy. 
Histopathologic subtyping of ACL and degree of dif- 
ferentiation was performed according to criteria of the 
World Health Organization 17by one pathologist, who did 
not know the clinical results. 
ACL was divided into acinar adenocarcinoma, papil- 
lary adenocarcinoma, bronchioloalveolar carcinoma, 
and solid carcinoma with mucus formation. Differenti- 
ation was divided into high, moderate, and low degrees 
of differentiation. Bronchiotoalveolar carcinoma was 
defined as highly differentiated, and solid carcinoma with 
mucus formation was defined as poorly differentiated. 17 
The pretreatment and treatment variables recorded 
included stage of disease, operation type, pulmonary 
symptoms, performance status, weight loss, age, gender, 
hemoglobin, leukocyte count, lactate dehydrogenase, as- 
partate aminotransferase, and alkaline phosphotases) 6' 18 
Patient survival was recorded, and autopsy reports were 
requested in case of death. No patients were lost to 
follow-up. 
The autopsy records were reviewed for organs with 
macroscopic or microscopic evidence of metastasis. 
Each organ, including sites in the central nervous 
system, was regarded as one site of metastasis; the 
specific number of metastases to each organ was not 
recorded. 
The clinical part of the study was performed according 
to the Helsinki II declaration. 
Nonparametric methods were used, with the X 2 test 
used for comparison of proportions and the Mann- 
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Table II. Organs with metastatic nvolvement a autopsy among 35 patients urviving more than 30 days after 
complete resection of stage I or H ACL 
Stage I Stage H Total 
No. positive/ No. positive/ No. positive/ 
Site No. examined % No. examined % No. examined % 
Mediastinum 7/23 30.4 8/12 66.7 15/35 42.9 
Liver* 5/23 21.7 8/12 66.7 13/35 37.1 
Brain 7/14 50 0/7 0 7/21 33.3 
Secondary lung 5/23 21.7 6/32 50.0 11/35 31.4 
Primary lungt 4/23 17.4 7/12 58.3 11/35 31.4 
Bones 3/32 13.0 4/11 36.7 7/34 20.6 
Pleura 2/23 8.7 5/12 41.7 7/35 20.0 
Kidney 3/23 13.2 3/12 25.0 6/35 17.1 
Adrenal glands 2/23 8.7 4/12 33.3 6/35 17.1 
Meninges 2/13 15.4 1/7 14.3 3/20 15.0 
Spinal cord 1/1 100 1/1 100 2/2 100 
Abdomen 2/13 8.7 1/12 8.3 3/35 8.6 
Pericardium 0/23 0 3/12 25.0 3/35 8.6 
Spleen 2/23 8.7 1/12 8.3 3/35 8.6 
Heart - 0/23 0 2/12 16.7 2/35 5.7 
Skin 1/22 4.5 0/11 0 1/33 3.0 
Urinary bladder 0/23 0 1/12 8.3 1/35 2.9 
Esophagus, tomach 1/23 4.3 0/12 0 1/35 2.9 
Trachea 1/23 4.3 0/12 0 1/35 2.9 
Thyroid gland 0/23 0 0/12 0 0/35 0 
Pulmonary artery 0/23 0 0/12 0 0/35 0 
Aorta 0/23 0 0/12 0 0/35 0 
Pancreas 0/23 0 0/12 0 0/35 0 
Testis/ovary 0/23 0 0/12 0 0/35 0 
*Significant difference between stage I and II, p = 0.03, Fisher's exact est. 
?Significant difference between stage I and II, p = 0.04, Fisher's exact est. 
Whitney U test for comparison ofdiscontinuous numeric 
variables between groups. 
Results 
A total of 137 patients with stage I or stage II ACL 
underwent complete resection during a 41/z-year pe- 
riod from February 1981 through July 1985; by Octo- 
ber 1993, 108 of these patients had died. Forty-three 
autopsies were performed, corresponding to an au- 
topsy rate of 39.8%. Eight patients died within 30 days 
after operation, and autopsies were performed on all. 
These patients were excluded from the general de- 
scription of the metastatic pattern and analysis in 
relation to clinical parameters. No metastatic sites 
were found at autopsy in any of these eight patients. 
Results of pretreatment characteristics for these eight 
patients are given in Table I, together with those of the 
129 patients who survived more than 30 days. The 
pretreatment characteristics did not differ significantly 
between the eight patients with early perioperative 
death and the patients with longer survival times. 
The metastatic pattern observed at autopsy for 35 
patients who survived longer than 30 days after 
operation is given in Table II. The most common 
sites of metastasis were intrathoracic, with lung 
metastases, mediastinal lymph node involvement, 
and involvement of pleura, heart, and pericardium 
as frequent manifestations. Significant differences in
frequency of organ involvement between stage I and 
stage II ACL were observed for primary lung (p = 
0.04) and liver (p = 0.03). The most common among 
the extrathoracic metastatic sites were liver, brain, 
bones, adrenal glands, and kidneys. The median 
number of organs with tumor involvement was 2 
(range 0 to 10); the median umbers of intrathoracic 
and extrathoracic sites with tumor involvement were 
1 (range 0 to 5) and 1 (range 0 to 7), respectively. 
The influences of clinical variables on the meta- 
static pattern are shown in Table III. The analyses 
were performed both for total number of metastatic 
sites and for intrathoracic (regional) sites and ex- 
trathoracic (distant) sites separately. Significant dif- 
ferences were observed between initial stage I and 
stage II disease, both with respect to the total 
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number of metastases and the number of intratho- 
racic metastases, but not for the number of extratho- 
racic metastases. Patients with stage I disease had 
fewer metastases (median 1; range 0 to 10) than did 
those with stage II disease (median 5; range 0 to 8; 
p = 0.015). They also had fewer intrathoracic me- 
tastases (median 0; range 0 to 4) than those with 
stage II disease (median 3; range 3 to 5;p = 0.012). 
Patients urviving less than 1 year had significantly 
more extrathoracic (distant) sites than patients with 
longer survival times. Furthermore, patients with 
lesions having highly differentiated histologic fea- 
tures had fewer extrathoracic metastatic sites (me- 
dian 0; range 0 to 3) than did patients with moderate 
or poorly differentiated tumors (median 1; range 0 
to 7) but did not have more regional sites. No other 
significant differences were seen regarding other 
pretreatment variables uch as gender, age, lactate 
dehydrogenase, performance status, histologic sub- 
type, or degree of differentiation. 
Discussion 
The observed ifference in total number of me- 
tastases between initial stage I and stage II disease 
could result from different biologic characteristics of 
the tumors. The more aggressive, poorly differenti- 
ated tumors had a higher stage at the time of 
diagnosis and also had a higher number of involved 
organs at the time of death, despite an apparently 
complete resection. In addition, the presence of 
more extrathoracic sites in short-term survivors 
could be explained by a higher metastatic potential, 
corresponding to a more aggressive behavior of the 
tumor. New molecular biology techniques, such as 
detection of epithelial cytokeratin component 18 by 
monoclonal antibodies, could give further informa- 
tion about this characteristicJ 9 
The fewer extrathoracic sites in highly differenti- 
ated tumors compared with moderate and poorly 
differentiated tumors may explain the previously 
reported observation that these tumors have a bet- 
ter prognosis with a slower clinical progression and 
longer survival. 16 
A high confidence for perioperative staging pro- 
cedures is suggested by the observation that no sites 
of residual disease were found in the eight patients 
who died within 30 days after operation. 
The general pattern of metastatic sites observed 
in this study is in accordance with previously pub- 
lished large, nonconsecutive s ries. 1°' 20-22 The most 
frequent sites of metastatic involvement in the 
Table III. Autopsy findings of metastases in relation 
to pretreatment variables for 35 patients urviving 
more than 30 days after complete resection for stage 
I or I IACL 
Test size 
No. of metastatic sites 
Intrathoracic: Extrathoracic: 
Total." median median median 
(range) (range) (range) 
Age (yr) 
Below 1 (0-8) 1 (0-5) 1 (0-6) 
Median (60.8), p 0.53 0.56 0.29 
Above 2 (0-10) 1 (0-4) 2 (0-7) 
Survival (mo) 
Below 2 (0-8) 0 (0-5) 1 (0-4) 
Median (23.4), p 0.18 0.59 0.11 
Above 2 (0-10) 1 (0-5) 1.5 (0-7) 
--<6 4 (1-7) 1,5 (0-3) 2,5 (1-4) 
vs, p 0.71 1.00 0.41 
All 2 (0-10) 1 (0-5) 1 (0-7) 
-<12 2 (1-10) 1 (0-4) 1 (0-7) 
vs, p 0.07 0.66 0.01 
All 2 (0-8) 0.5 (0-5) 1 (0-4) 
Lower quartile 2 (1-10) 1 (0-4) 2 (0-7) 
vs, p 0.22 0.34 0.19 
Higher quartile 2 (0-5) 0 (0-4) 1 (0-4) 
present study and in previous tudies are shown in 
Table IV. 
Discordance between the frequencies of meta- 
static organ involvement in the present study and 
those in previously reported studies are probably 
caused by imbalance in the frequency of the major 
histologic types of the tumors treated and also by 
different reatments for the study populations, in- 
cluding treatment modalities uch as surgery, radio- 
therapy, and chemotherapy. Accordingly, the figures 
cannot be directly compared. However, some con- 
clusions can be extracted from the data. Among 
these is that regional intrathoracic disease activity, 
including metastasis to mediastinal lymph nodes, 
lungs, heart, and pericardium, is common of the 
time of death in spite of an apparently complete 
resection. 
Local rate of metastasis n 140 patients who died 
within 30 days after resection has been reported to 
be 28.5%, and in those with adenocarcinoma up to 
43%. 23 Later studies based on pattern of metastasis 
with clinical implications on treatment of relapse 
reported local recurrence rates from 11% to 
18%.6. 24, 25 Compared with autopsy data, these fig- 
ures are smaller because they include the inaccuracy 
of the diagnostic tools and clinical decisions and 
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Table IV. Metastatic pattern in the present study and in previous tudies 
Involvement (%) 
Feld et aL 2° 
Organs Present study Gulluzzi et al /° (site of  first relapse) Oehler et aL e2 Notter et al. 21 
Mediastinum 42.9 nr 4 NR NR 
Liver 37.1 39.3 NR* 13.0 38.5 
Brain/central nervous ystem 33.3 25.7 22 6.0 21.4 
Lung (secondary) 31.4 NR 14 NR 24.8 
Bones 20.6 14.6 12 12.4 26.7 
Adrenals 17.1 33.5 NR* 7.6 29.4 
Kidney 17.1 15.4 NR* 8.8 18.1 
Spleen 8.6 5.3 NR* NR NR 
Heart/pericardium 8.6 nr NR* NR 9.3 
nr, Not reported; no values given in the material. 
*Total percentage of "other distant sites" = 23. 
Table V. Extent of surgical treatment and summary of metastatic pattern in 43 autopsies of patients with stage 
I and stage H adenocarcinoma of the lung 
Lobectomy * Bilobect omy * Pneumonectomy * Total* 
Autopsy summary 
Stage I
Local (only) 3 0 0 3 
Distant 6 0 1 7 
Both 4 0 3 7 
None 5 (2) 2 (1) 3 (1) 10 
Total 18 (2) 2 (1) 7 (1) 27 (4) 
Stage II 
Local (only) 1 0 ' 1 2 
Distant 0 0 3 3 
Both 2 3 1 6 
None 2 (1) 0 3 (3) 5 
Total 5 (1) 3 8 (3) 16 (4) 
*Total number of patients (number of perioperative d aths in parentheses). 
represent an earlier step in the progression of the 
disease than the present autopsy data did. Only 5 of 
the 35 patients who survived more than 30 days after 
operation and had an autopsy died with local recur- 
rence only, and our data did not allow firm conclu- 
sions on the relation of metastasis to the extent of 
the surgical procedure (Table V). Of the 15 patients 
who died without metastatic disease, 8 died in the 
postoperative p riod. The remaining 7 patients died 
of concurrent diseases: 3 of acute myocardial infarc- 
tion, 1 of pulmonary embolism, 1 of acute peri- 
carditis, 1 of pneumonia nd acute pleuritis, and 1 of 
a new primary cancer (squamous cell carcinoma in 
the esophagus). 
These results point toward the need for better 
procedures for staging of minimal, locally advanced 
disease; the combination of computed tomography 
and mediastinoscopy is recommended in the preop- 
erative evaluation. 26' 27 
Common distant sites of relapse, both in the 
present study and in previous studies, 1°'2°-22 are 
liver, brain, bones, adrenals, and kidneys (see Table 
IV). These sites should be monitored in studies of 
adjuvant reatment of patients having complete re- 
section to achieve accurate valuation of relapse site 
and recurrence-flee survival. 
Metastatic spread to the spleen was more preva- 
lent than previously reported and metastases to the 
pancreas and abdominal nodes were less prevalent. 
These differences may have been caused by real 
biologic differences between ACL and other histo- 
logic types of NSCLC, or they may be the result of 
stocastic variation caused by the limited number of 
patients in the studies compared in Table IV. 
In conclusion, among patients with completely 
resected ACL, a highly differentiated histology and 
a survival time exceeding 1 year were associated with 
a significantly lower incidence of extrathoracic 
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spread. Inversely, patients with poorly differentiated 
tumors and a short survival time (less than 1 year) 
had a significantly higher incidence of extrathoracic 
metastatic disease, even those initially having stage I
disease. Locoregional control of disease is recog- 
nized as a well-defined problem, and adjuvant reat- 
ment is needed in ACL to improve the prognosis. 
Highly effective adjuvant chemotherapy regimens 
in ACL have not yet been defined, even though 
promising results have been obtained from phase II 
trials. Fut~tre aspects could be to evaluate treatment 
results from adjuvant, postoperative chemotherapy 
in completely resected stage I and II ACL, especially 
in patients with such prognostic factors as poor 
differentiation with a high risk of distant metastasis 
and thereby a short predicted survival time. 
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